Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Antisense oligonucleotides for therapeutic intervention.

S L Eck¹, G J Nabel

¹Howard Hughes Medical Institute, University of Michigan Medical Center, Department of Internal Medicine, Ann Arbor 48109-0650.

Current Opinion in Biotechnology

|December 1, 1991

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.

Journal of virology·2015

Same author

Methods for liposome-mediated gene transfer to the arterial wall.

Methods in molecular medicine·2014

Same author

Methods for liposome-mediated gene transfer to tumor cells in vivo.

Methods in molecular medicine·2014

Same author

Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans.

Clinical and vaccine immunology : CVI·2012

Same author

Gene transfer and cardiovascular disease.

Trends in cardiovascular medicine·2011

Same author

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.

Vaccine·2010

Same journal

Microbial C1 assimilation pathways for chemical synthesis: from native metabolism to synthetic design.

Current opinion in biotechnology·2026

Same journal

Medicinal plants fermentation: current knowledge and perspectives.

Current opinion in biotechnology·2026

Same journal

Fermented foods: lessons learned from metagenomics.

Current opinion in biotechnology·2026

Same journal

Microfluidic platforms for the transient transfection of mammalian cells: recent developments and challenges.

Current opinion in biotechnology·2026

Same journal

Harvesting insights from recent advances in yeast genomics for predictable and precision wine fermentation.

Current opinion in biotechnology·2026

Same journal

Minimal enzyme cascades for the aromatic-to-aromatic upgrading of lignin monomers.

Current opinion in biotechnology·2026

See all related articles

Antisense oligonucleotide technology shows promise for treating diseases, but new chemical derivatives and target sequences are needed before human application is possible.

Area of Science:

Molecular Biology
Pharmacology
Biotechnology

Background:

Antisense oligonucleotide (ASO) technology offers a targeted approach to gene silencing.
Significant progress has been made in identifying optimal sequences for ASO efficacy.
Novel chemical modifications of oligonucleotides are under active investigation to improve their properties.

Purpose of the Study:

To review the current state of antisense oligonucleotide technology.
To discuss the potential therapeutic applications of ASOs.
To identify limitations hindering human administration.

Main Methods:

Review of recent advancements in oligonucleotide chemistry.
Analysis of sequence selection strategies for ASO targeting.

Related Experiment Videos

Evaluation of existing data on ASO efficacy and safety.

Main Results:

Advances in defining optimal target sequences for antisense oligonucleotide technology.
Investigation into new chemical derivatives of oligonucleotides.
Exploration of ASO potential in neoplastic, viral, and parasitic diseases.

Conclusions:

Antisense oligonucleotide technology has potential therapeutic applications.
Further research and development are required to overcome current limitations.
ASOs are not yet suitable for human administration due to discussed reasons.